National Sleep Foundation Partners with Tempur-Pedic to Research Sleep Disruptions in America
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy SGI?
Source: Newsfilter
- Research Collaboration Launched: The National Sleep Foundation (NSF) has partnered with Tempur-Pedic to combine nationally representative research with SleepTracker-AI® data, aiming to gain insights into the factors disrupting Americans' sleep, thereby providing data-driven support for improving sleep health.
- Data Integration Analysis: This research will merge subjective and objective data to reveal how different demographics, regions, and sleep habits affect sleep quality, assisting in the development of targeted solutions to address the growing sleep issues.
- Sleep Awareness Week Campaign: Tempur-Pedic, as a Gold sponsor of NSF's 2026 Sleep Awareness Week, will enhance public awareness of the importance of sleep health, with an anticipated reach to millions of Americans.
- Long-term Commitment: Since its establishment in 1990, NSF has been dedicated to improving health and well-being through sleep education and advocacy, while Tempur-Pedic leverages its industry-leading innovations to advance its mission of enhancing sleep globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGI
Wall Street analysts forecast SGI stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 70.670
Low
86.00
Averages
98.60
High
110.00
Current: 70.670
Low
86.00
Averages
98.60
High
110.00
About SGI
Somnigroup International Inc. is a bedding company. The Company is engaged in the business of designing, manufacturing, distributing and retailing. Its portfolio of product brands includes various brands, including Tempur-Pedic, Sealy and Stearns & Foster. Its portfolio of retail brands includes Mattress Firm, Dreams, Tempur-Pedic retail stores, SOVA and a variety of other retail brands internationally, which operate in various countries. The Company operates in three segments: Tempur Sealy North America, Tempur Sealy International and Mattress Firm. It sells products through two channels in each operating business segment: Wholesale and Direct. Its Wholesale channel consists of third-party retailers, including third-party distribution, hospitality and healthcare. Its Direct channel includes Company-owned stores, e-commerce and call centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Somnigroup Reports 12% Sales Growth in Q1 2026
- Strong Financial Performance: Somnigroup International reported net sales of $1.8 billion for Q1 2026, reflecting a 12.3% year-over-year increase, demonstrating the company's ability to achieve robust growth amidst market challenges, thereby boosting investor confidence.
- Significant EPS Growth: The company's earnings per share (EPS) surged from a loss of $0.17 in 2025 to $0.49 in 2026, marking a 388.2% increase, which indicates a substantial improvement in profitability and is expected to positively impact the stock price.
- Outstanding Mattress Firm Performance: Mattress Firm's net sales increased by 49.2% to $885.9 million, primarily due to a full quarter of sales data, indicating successful integration of the acquisition and strong market demand.
- Optimistic Future Outlook: The company anticipates adjusted EPS for 2026 to range between $3.00 and $3.40, representing an approximate 19% increase from the midpoint of 2025, reflecting management's confidence in future performance, which may attract more investor interest.
See More
Somnigroup Declares Q2 Cash Dividend of $0.17 per Share
- Dividend Declaration: Somnigroup International Inc. has announced a cash dividend of $0.17 per share for the second quarter, payable on June 4, 2026, to shareholders of record as of May 21, 2026, reflecting the company's commitment to shareholder returns and stable financial health.
- Global Market Leadership: As the world's leading bedding company, Somnigroup excels in design, manufacturing, distribution, and retail, dedicated to meeting the evolving needs of consumers in over 100 countries, further solidifying its market leadership.
- Brand Portfolio Strength: Somnigroup's portfolio includes renowned brands such as Tempur-Pedic®, Sealy®, Stearns & Foster®, and Sleepy's®, leveraging a global omni-channel platform to provide personalized retail experiences that enhance customer loyalty and drive sales growth.
- Long-term Value Commitment: The company is focused on delivering long-term value for shareholders through prudent capital allocation, emphasizing its core value of Doing the Right Thing while committing to environmental protection and community support, showcasing its corporate social responsibility.
See More
Leggett & Platt Reports 10% Decline in Q1 Sales Amid Market Challenges
- Sales Performance Decline: Leggett & Platt reported first-quarter sales of $918 million, a 10% decrease year-over-year, reflecting weak demand in the U.S. mattress market, particularly in residential sectors, leading to overall performance falling short of expectations.
- EBIT and Profit Drop: The first-quarter EBIT was $45 million, down 29% from $63 million in the same period last year, with EBIT margin declining from 6.2% to 4.8%, indicating a dual impact from cost pressures and insufficient market demand.
- Merger Agreement Progress: Leggett has signed a merger agreement with Somnigroup, anticipated to close by the end of 2026, which will provide shareholders with an opportunity to participate in future growth, highlighting the company's commitment to long-term strategic goals.
- Increased Cost Pressures: The company faces heightened cost pressures due to rising transportation costs and chemical prices driven by the war in Iran, and while Leggett is implementing product and sourcing measures to mitigate these impacts, future profitability remains a concern.
See More
Mattress Firm Launches Memorial Day Sale to Boost Summer Sleep
- Promotion Duration: Mattress Firm is launching a nationwide Memorial Day Sale offering up to $700 off on select mattresses from April 29 to June 9, aimed at helping consumers enhance their sleep quality during the busy summer season, coinciding with significant events like graduations and Mother's Day.
- Sleep Survey Findings: According to Mattress Firm's State of Sleep survey, Americans average only 6.6 hours of sleep per night, below the 7.1 hours they deem necessary, with only 10 'perfect' sleep nights per month, highlighting a pressing demand for quality sleep that this promotion addresses.
- Product Discounts: During the sale, customers can enjoy various offers, including a free adjustable base valued at $299.99 with qualifying mattress purchases, or a Sleepy's Basic Innerspring Firm Mattress for just $219.99, significantly lowering the barrier to purchase and enhancing product appeal.
- Special Discounts: Specific groups such as military personnel, teachers, and students can receive an additional 10%-20% off, reflecting Mattress Firm's commitment to social responsibility while also strengthening its competitive position in the market and attracting more consumers to participate in the sale.
See More
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Stock Price Movements of Various Companies
- Oracle AI Capabilities Boost: At the Customer Edge Summit, Oracle announced that its AI platform helped residential utility customers save $369 million in 2025, leading to a more than 9% increase in shares, indicating enhanced competitiveness in the cloud computing sector.
- Conagra CEO Transition: Conagra announced that John Brase will take over as CEO on June 1, resulting in a more than 5% drop in shares, reflecting market unease over leadership changes, with shares down over 17% in 2026.
- Allogene Therapeutics Clinical Success: The biotech company saw its shares soar nearly 30% after positive phase 2 data showed its CAR T treatment significantly improved cancer cell eradication in lymphoma patients, laying a strong foundation for future product line expansion.
- Goldman Sachs Earnings Beat: Despite its fixed income trading falling short of expectations, Goldman Sachs posted an earnings and revenue beat in its first-quarter report, with shares down over 2%, indicating market caution regarding its future performance.
See More
Somnigroup Reports 12% Sales Growth in Q1 2026
- Strong Financial Performance: Somnigroup International reported net sales of $1.8 billion for Q1 2026, reflecting a 12.3% year-over-year increase, demonstrating the company's ability to achieve robust growth amidst market challenges, thereby boosting investor confidence.
- Significant EPS Growth: The company's earnings per share (EPS) surged from a loss of $0.17 in 2025 to $0.49 in 2026, marking a 388.2% increase, which indicates a substantial improvement in profitability and is expected to positively impact the stock price.
- Outstanding Mattress Firm Performance: Mattress Firm's net sales increased by 49.2% to $885.9 million, primarily due to a full quarter of sales data, indicating successful integration of the acquisition and strong market demand.
- Optimistic Future Outlook: The company anticipates adjusted EPS for 2026 to range between $3.00 and $3.40, representing an approximate 19% increase from the midpoint of 2025, reflecting management's confidence in future performance, which may attract more investor interest.
See More
Somnigroup Declares Q2 Cash Dividend of $0.17 per Share
- Dividend Declaration: Somnigroup International Inc. has announced a cash dividend of $0.17 per share for the second quarter, payable on June 4, 2026, to shareholders of record as of May 21, 2026, reflecting the company's commitment to shareholder returns and stable financial health.
- Global Market Leadership: As the world's leading bedding company, Somnigroup excels in design, manufacturing, distribution, and retail, dedicated to meeting the evolving needs of consumers in over 100 countries, further solidifying its market leadership.
- Brand Portfolio Strength: Somnigroup's portfolio includes renowned brands such as Tempur-Pedic®, Sealy®, Stearns & Foster®, and Sleepy's®, leveraging a global omni-channel platform to provide personalized retail experiences that enhance customer loyalty and drive sales growth.
- Long-term Value Commitment: The company is focused on delivering long-term value for shareholders through prudent capital allocation, emphasizing its core value of Doing the Right Thing while committing to environmental protection and community support, showcasing its corporate social responsibility.
See More
Leggett & Platt Reports 10% Decline in Q1 Sales Amid Market Challenges
- Sales Performance Decline: Leggett & Platt reported first-quarter sales of $918 million, a 10% decrease year-over-year, reflecting weak demand in the U.S. mattress market, particularly in residential sectors, leading to overall performance falling short of expectations.
- EBIT and Profit Drop: The first-quarter EBIT was $45 million, down 29% from $63 million in the same period last year, with EBIT margin declining from 6.2% to 4.8%, indicating a dual impact from cost pressures and insufficient market demand.
- Merger Agreement Progress: Leggett has signed a merger agreement with Somnigroup, anticipated to close by the end of 2026, which will provide shareholders with an opportunity to participate in future growth, highlighting the company's commitment to long-term strategic goals.
- Increased Cost Pressures: The company faces heightened cost pressures due to rising transportation costs and chemical prices driven by the war in Iran, and while Leggett is implementing product and sourcing measures to mitigate these impacts, future profitability remains a concern.
See More
Mattress Firm Launches Memorial Day Sale to Boost Summer Sleep
- Promotion Duration: Mattress Firm is launching a nationwide Memorial Day Sale offering up to $700 off on select mattresses from April 29 to June 9, aimed at helping consumers enhance their sleep quality during the busy summer season, coinciding with significant events like graduations and Mother's Day.
- Sleep Survey Findings: According to Mattress Firm's State of Sleep survey, Americans average only 6.6 hours of sleep per night, below the 7.1 hours they deem necessary, with only 10 'perfect' sleep nights per month, highlighting a pressing demand for quality sleep that this promotion addresses.
- Product Discounts: During the sale, customers can enjoy various offers, including a free adjustable base valued at $299.99 with qualifying mattress purchases, or a Sleepy's Basic Innerspring Firm Mattress for just $219.99, significantly lowering the barrier to purchase and enhancing product appeal.
- Special Discounts: Specific groups such as military personnel, teachers, and students can receive an additional 10%-20% off, reflecting Mattress Firm's commitment to social responsibility while also strengthening its competitive position in the market and attracting more consumers to participate in the sale.
See More
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Stock Price Movements of Various Companies
- Oracle AI Capabilities Boost: At the Customer Edge Summit, Oracle announced that its AI platform helped residential utility customers save $369 million in 2025, leading to a more than 9% increase in shares, indicating enhanced competitiveness in the cloud computing sector.
- Conagra CEO Transition: Conagra announced that John Brase will take over as CEO on June 1, resulting in a more than 5% drop in shares, reflecting market unease over leadership changes, with shares down over 17% in 2026.
- Allogene Therapeutics Clinical Success: The biotech company saw its shares soar nearly 30% after positive phase 2 data showed its CAR T treatment significantly improved cancer cell eradication in lymphoma patients, laying a strong foundation for future product line expansion.
- Goldman Sachs Earnings Beat: Despite its fixed income trading falling short of expectations, Goldman Sachs posted an earnings and revenue beat in its first-quarter report, with shares down over 2%, indicating market caution regarding its future performance.
See More
